Loading…
Loading…
Charles River Laboratories International Inc
NYSE · Stock Profile · Market Cap $7.73B
Current Price
$157.11
+2.21%GoodMoat Value
$297.19
89.2% undervaluedFree cash flow has been growing at 22.4% annually.
Forward estimates use 22.4% FCF growth (CAGR)
Net Debt: 2.4B
1.0B
FY24
1.0B
FY24
4.0B
FY24
984M
FY25
1.0B
FY25
1.0B
FY25
4.0B
FY25
94M
FY24
70M
FY24
22M
FY24
25M
FY25
52M
FY25
54M
FY25
—
FY25
Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company has been supplying research models to the drug development industry. The Company is engaged in the production and sale of rodent research model strains, principally genetically and microbiologically defined purpose-bred rats and mice. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. In August 2012, the Company acquired Accugenix, Inc. In January 2013, the Company acquired 75% ownership of Vital River.
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYSE
Country
Massachusetts, USA
Free cash flow has been growing at 22.4% annually.
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Run a full DCF analysis with customizable assumptions
Open DCF Calculator →Graham Number, PEG-based, and Earnings-based models
View Fair Value →This stock does not currently pay a dividend.
Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company has been supplying research models to the drug development industry. The Company is engaged in the production and sale of rodent research model strains, principally genetically and microbiologically defined purpose-bred rats and mice. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. In August 2012, the Company acquired Accugenix, Inc. In January 2013, the Company acquired 75% ownership of Vital River.
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYSE
Country
Massachusetts, USA